The FDA Tuesday approved Samsung Bioepis’ Hadlima (adalimumab-bwwd), referencing Humira.
This article has been updated.
The FDA on Tuesday approved Samsung Bioepis’ Hadlima (adalimumab-bwwd), referencing Humira.
Hadlima, a subcutaneous injection, was cleared for rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn disease, ulcerative colitis, and plaque psoriasis.
"With the approval of Hadlima, we are proud to have three anti-TNF biosimilars approved in the US. We believe the US healthcare system can benefit from biosimilars, which could play a critical role in broadening access to treatment options for patients with autoimmune conditions across the country," said Hee Kyung Kim, senior vice president and head of regulatory affairs, Samsung Bioepis, in a statement. “We remain committed to advancing our strong pipeline of biosimilar candidates, so that more patients and healthcare systems can benefit from biosimilars.”
A pivotal pharmacokinetic (PK) study of the biosimilar in healthy volunteers was conducted in Germany. This study was a randomized, single-blind, 3-arm, parallel group, single-dose phase 1 study in 189 healthy volunteers who were randomized to receive the biosimilar or the reference. All of the 90% confidence intervals (CIs) for the geometric least squares means ratios of primary PK parameters for the biosimilar and the EU and US reference products fell within the prespecified equivalence margin of 0.8 to 1.25.
The biosimilar was also studied in a phase 3 study in patients with moderate to severe rheumatoid arthritis. In the study, patients who failed to respond adequately to methotraxate were randomized to receive the biosimilar (n = 269) or the reference (n = 273) at a dose of 40 mg every other week. The primary efficacy end point was the response rate based on the American College of Rheumatology 20% improvement criteria (ACR20) at week 24.
The ACR20 response rate at week 24 was equivalent between the 2 arms (72.4% and 72.2%, respectively), and the difference in ACR20 response rate was 0.1% (95% CI, −7.83% to 8.13%) within the prespecified equivalence margin of plus or minus 15%. Both adalimumabs were well tolerated and had comparable safety profiles.
The biosimilar is also approved in the European Union, where it has launched in numerous markets. However, Samsung Bioepis and Biogen, with partner Merck, will not be free to launch the product in the United States until June 30, 2023, under the terms of a patent litigation settlement with Humira’s sponsor, AbbVie.
Hadlima, which is approved as Imraldi in the European Union, joins Amgen’s Amjevita, Boehringer Ingelheim’s Cyltezo, and Sandoz’s Hyrimoz as FDA-approved, but unlaunched, biosimilar adalimumab products.
Earlier in the day Tuesday, the FDA approved Pfizer’s rituximab biosimilar, Ruxience (rituximab-pvvr), referencing Rituxan.
References
1. Shin D, Kim Y, Kim HS, Fuhr R, Kornicke T. A phase 1 pharmacokinetic study comparing SB5, an adalimumab biosimilar, and adalimumab reference product (Huimra) in healthy subjects. Ann Rheum Dis. 2015;74:459-460. ard.bmj.com/content/74/Suppl_2/459.3.info
2. Weinblatt ME, Baranauskaite A, Niebrzydowski J, et al. Phase III Randomized study of SB5, an adalimumab biosimilar, versus reference adalimumab in patients with moderate‐to‐severe rheumatoid arthritis. Arthritis Rheumatol. 2018; 70(1):40-48. doi: 10.1002/art.40336.
Enhancing Adoption of Infused Biosimilars for a Sustainable Future
October 30th 2024An IQVIA report highlights challenges to the sustainability of infused biosimilars in the US, citing rebate walls and reimbursement policies, and proposes key solutions to enhance adoption and benefits for all stakeholders.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Strengthening the Supply Chain: Key Insights From FDA Commissioner Dr Robert Califf
October 25th 2024At the GRx+Biosims conference, FDA Commissioner Robert Califf, MD, stressed the urgent need for data transparency in the global supply chain and the role of collaboration and artificial intelligence in ensuring the resilience of biosimilar and generic drug production.
FDA and Industry Experts Unpack Biosimilar Device Requirements
October 23rd 2024At the GRx+Biosims 2024 conference, a panel of industry experts and FDA officials discussed evolving device requirements for biosimilars and interchangeable biosimilars, highlighting new approaches to comparative use human factors studies, regulatory challenges, and alternative validation methods.